Principal Financial Group Inc. Sells 22,374 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Principal Financial Group Inc. decreased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 14.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 136,260 shares of the biotechnology company’s stock after selling 22,374 shares during the quarter. Principal Financial Group Inc. owned 0.06% of ADMA Biologics worth $899,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Alberta Investment Management Corp increased its holdings in shares of ADMA Biologics by 32.4% during the 4th quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock worth $2,083,000 after purchasing an additional 112,831 shares during the period. GSA Capital Partners LLP boosted its position in shares of ADMA Biologics by 87.7% during the 3rd quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock valued at $867,000 after acquiring an additional 113,184 shares in the last quarter. Qube Research & Technologies Ltd boosted its position in shares of ADMA Biologics by 22.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock valued at $4,313,000 after acquiring an additional 224,696 shares in the last quarter. American Century Companies Inc. boosted its position in shares of ADMA Biologics by 20.8% during the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after acquiring an additional 840,761 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of ADMA Biologics by 417.3% during the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 75,213 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $11.46 on Friday. The firm has a market cap of $2.66 billion, a PE ratio of -573.00 and a beta of 0.55. ADMA Biologics, Inc. has a 12 month low of $3.06 and a 12 month high of $11.68. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91. The company’s 50-day moving average price is $9.60 and its two-hundred day moving average price is $6.94.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.03. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The company had revenue of $81.90 million for the quarter, compared to analyst estimates of $77.28 million. During the same period in the prior year, the business earned ($0.03) earnings per share. ADMA Biologics’s quarterly revenue was up 43.9% on a year-over-year basis. On average, equities analysts anticipate that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ADMA. Raymond James lifted their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research report on Friday, May 10th. Mizuho lifted their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. HC Wainwright lifted their target price on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Finally, Cantor Fitzgerald boosted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, May 10th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $11.00.

Insider Transactions at ADMA Biologics

In other news, CEO Adam S. Grossman sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the transaction, the chief executive officer now directly owns 2,081,475 shares in the company, valued at $22,313,412. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.70% of the stock is owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.